Transferring Your Cell Line With Confidence: Accelerating Biologics Development Through Adaptable Cell Line Integration And End-To-End Support

By Tracy Root, Principal Group Leader, and Prafulla Mahajan, Ph.D., Senior Principal Scientist, Lonza

Chinese Hamster Ovary (CHO) cells, the leading choice of cell line for producing recombinant therapeutic proteins, have set the standard for large-scale biologic drug manufacturing. Over time, several variants of the CHO cell with diverse characteristics have emerged with advances in science and technology. As a result, it is more important than ever to select optimal process conditions that can help achieve maximum cell growth and product quality. Other considerations when executing this critical bioprocessing step include the complexity of the express product, the capacity of the development site, available equipment, and the expertise of the team.

Leveraging its extensive experience and regulatory expertise, Lonza has developed robust strategies that support the production of various molecule types and mammalian expression technologies, enabling the efficiency and reproducibility essential for commercial success. Read the case studies outlined in this article to learn more about these strategies and other details about how Lonza experts drive high-quality biologics manufacturing.